Literature DB >> 20501690

Rise of oxyntomodulin in response to oral glucose after gastric bypass surgery in patients with type 2 diabetes.

Blandine Laferrère1, Nicholas Swerdlow, Baani Bawa, Sara Arias, Mousumi Bose, Blanca Oliván, Julio Teixeira, James McGinty, Kristina I Rother.   

Abstract

CONTEXT: The mechanisms by which Roux-en-Y gastric bypass surgery (GBP) results in sustained weight loss and remission of type 2 diabetes are not fully understood.
OBJECTIVE: We hypothesized that the anorexic hormone oxyntomodulin (OXM) might contribute to the marked weight reduction and the rapid improvement in glucose metabolism observed in morbidly obese diabetic patients after GBP.
METHODS: Twenty obese women with type 2 diabetes were studied before and 1 month after GBP (n=10) or after a diet-induced equivalent weight loss (n=10). Patients from both groups were matched for age, body weight, body mass index, and diabetes duration and control. OXM concentrations were measured during a 50-g oral glucose challenge before and after weight loss.
RESULTS: At baseline, OXM levels (fasting and stimulated values) were indistinguishable between the GBP and the diet group. However, OXM levels rose remarkably in response to an oral glucose load more than 2-fold (peak, 5.25+/-1.31 to13.8+/-16.2 pmol/liter; P=0.025) after GBP but not after diet. The peak of OXM after glucose was significantly correlated with glucagon-like peptide-1 and peptide YY3-36.
CONCLUSIONS: Our data suggest that the observed changes in OXM primarily occur in response to GBP and not as a consequence of weight loss. These changes were observed early after surgery and occurred in parallel with previously reported increases in incretins and peptide YY. We speculate that the combination of gut hormone changes is essential for the improved glucose homeostasis and may partially explain the success of this surgery on diabetes resolution and weight loss.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20501690      PMCID: PMC2913033          DOI: 10.1210/jc.2009-2767

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

1.  Oxyntomodulin suppresses appetite and reduces food intake in humans.

Authors:  Mark A Cohen; Sandra M Ellis; Carel W Le Roux; Rachel L Batterham; Adrian Park; Michael Patterson; Gary S Frost; Mohammad A Ghatei; Stephen R Bloom
Journal:  J Clin Endocrinol Metab       Date:  2003-10       Impact factor: 5.958

2.  Oxyntomodulin-like immunoreactivity: diurnal profile of a new potential enterogastrone.

Authors:  A Le Quellec; A Kervran; P Blache; A J Ciurana; D Bataille
Journal:  J Clin Endocrinol Metab       Date:  1992-06       Impact factor: 5.958

3.  Glucagon-like peptide-1-(7-36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line.

Authors:  L Gros; B Thorens; D Bataille; A Kervran
Journal:  Endocrinology       Date:  1993-08       Impact factor: 4.736

4.  Oxyntomodulin inhibits food intake in the rat.

Authors:  C L Dakin; I Gunn; C J Small; C M Edwards; D L Hay; D M Smith; M A Ghatei; S R Bloom
Journal:  Endocrinology       Date:  2001-10       Impact factor: 4.736

5.  A pure enteroglucagon, oxyntomodulin (glucagon 37), stimulates insulin release in perfused rat pancreas.

Authors:  C Jarrousse; D Bataille; B Jeanrenaud
Journal:  Endocrinology       Date:  1984-07       Impact factor: 4.736

6.  Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract.

Authors:  M A Ghatei; L O Uttenthal; N D Christofides; M G Bryant; S R Bloom
Journal:  J Clin Endocrinol Metab       Date:  1983-09       Impact factor: 5.958

7.  Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.

Authors:  Laurie L Baggio; Qingling Huang; Theodore J Brown; Daniel J Drucker
Journal:  Gastroenterology       Date:  2004-08       Impact factor: 22.682

8.  Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs.

Authors:  F G Baldissera; J J Holst; S Knuhtsen; L Hilsted; O V Nielsen
Journal:  Regul Pept       Date:  1988-05

9.  Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial.

Authors:  Katie Wynne; Adrian J Park; Caroline J Small; Michael Patterson; Sandra M Ellis; Kevin G Murphy; Alison M Wren; Gary S Frost; Karim Meeran; Mohammad A Ghatei; Stephen R Bloom
Journal:  Diabetes       Date:  2005-08       Impact factor: 9.461

10.  Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.

Authors:  Alessandro Pocai; Paul E Carrington; Jennifer R Adams; Michael Wright; George Eiermann; Lan Zhu; Xiaobing Du; Aleksandr Petrov; Michael E Lassman; Guoqiang Jiang; Franklin Liu; Corey Miller; Laurie M Tota; Gaochao Zhou; Xiaoping Zhang; Michael M Sountis; Alessia Santoprete; Elena Capito'; Gary G Chicchi; Nancy Thornberry; Elisabetta Bianchi; Antonello Pessi; Donald J Marsh; Ranabir SinhaRoy
Journal:  Diabetes       Date:  2009-07-14       Impact factor: 9.461

View more
  46 in total

Review 1.  Beyond fast food and slow motion: weighty contributors to the obesity epidemic.

Authors:  G Cizza; K I Rother
Journal:  J Endocrinol Invest       Date:  2011-12-15       Impact factor: 4.256

Review 2.  Type 2 diabetes mellitus: a possible surgically reversible intestinal dysfunction.

Authors:  Priscila C Sala; Raquel S Torrinhas; Steven B Heymsfield; Dan L Waitzberg
Journal:  Obes Surg       Date:  2012-01       Impact factor: 4.129

Review 3.  Bariatric surgery: effects on the metabolic complications of obesity.

Authors:  Peter M Clifton
Journal:  Curr Atheroscler Rep       Date:  2012-04       Impact factor: 5.113

Review 4.  Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass.

Authors:  C Dirksen; N B Jørgensen; K N Bojsen-Møller; S H Jacobsen; D L Hansen; D Worm; J J Holst; S Madsbad
Journal:  Diabetologia       Date:  2012-04-27       Impact factor: 10.122

5.  Changes in post-prandial glucose and pancreatic hormones, and steady-state insulin and free fatty acids after gastric bypass surgery.

Authors:  Guilherme M Campos; Charlotte Rabl; Peter J Havel; Madhu Rao; Jean-Marc Schwarz; Morris Schambelan; Kathleen Mulligan
Journal:  Surg Obes Relat Dis       Date:  2013-07-20       Impact factor: 4.734

Review 6.  Roux-en-Y gastric bypass: effects on feeding behavior and underlying mechanisms.

Authors:  Sean Manning; Andrea Pucci; Rachel L Batterham
Journal:  J Clin Invest       Date:  2015-03-02       Impact factor: 14.808

Review 7.  Changes in Gut Microbiota and Hormones After Bariatric Surgery: a Bench-to-Bedside Review.

Authors:  Mohsen Tabasi; Fatemeh Ashrafian; Jamil Kheirvari Khezerloo; Sahar Eshghjoo; Ava Behrouzi; Seyed Alireza Javadinia; Farid Poursadegh; Sana Eybpoosh; Sara Ahmadi; Amin Radmanesh; Ahmadreza Soroush; Seyed Davar Siadat
Journal:  Obes Surg       Date:  2019-05       Impact factor: 4.129

Review 8.  Impact of bariatric surgery on type 2 diabetes: contribution of inflammation and gut microbiome?

Authors:  Jean Debédat; Chloé Amouyal; Judith Aron-Wisnewsky; Karine Clément
Journal:  Semin Immunopathol       Date:  2019-04-25       Impact factor: 9.623

Review 9.  From gut changes to type 2 diabetes remission after gastric bypass surgeries.

Authors:  Bing Li; Xinrong Zhou; Jiarui Wu; Huarong Zhou
Journal:  Front Med       Date:  2013-04-04       Impact factor: 4.592

Review 10.  Surgical weight loss: impact on energy expenditure.

Authors:  David Thivel; Katrina Brakonieki; Pascale Duche; Béatrice Morio; Morio Béatrice; Yves Boirie; Boirie Yves; Blandine Laferrère
Journal:  Obes Surg       Date:  2013-02       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.